Pinpointing key mechanisms in Alzheimer's disease development by Williams, Julie
Th  e reason most of us in the ﬁ  eld of complex genetics 
search for genes that contribute to disease development 
is that these genes will pinpoint mechanisms of primary 
importance to pathogenesis. Using a variation on this 
theme, van Exel and colleagues sought to identify traits 
associated with genetic risk before the development of 
Alzheimer’s disease (AD) [1]. Th   e study used an elegant 
design to identify primary events related to disease 
susceptibility in those at high genetic risk. By comparing 
middle-aged oﬀ  spring of AD cases with similar oﬀ  spring 
of nondemented parents, the authors observed increased 
proinﬂ  ammatory responses and increased hypertension 
in those at genetic risk. Th  ese individuals showed no 
overt  signs of cognitive decline. Th  e authors did not 
observe changes in cholesterol or inﬂ  ammatory markers 
circulating in the blood, which could indicate either that 
the disease process was not yet established or that these 
were not good biomarkers for AD development. Th  e 
greater proinﬂ  ammatory responses to inﬂ  ammatory chal-
lenge and the increased hypertension observed in those at 
high genetic risk, however, may indicate a pre  dis  position 
that contributes to AD development in the future.
Th   e idea that changes in inﬂ  ammation/innate immunity 
are associated with AD is not new. Numerous studies 
have shown markers of inﬂ  ammation to be increased in 
AD suﬀ   erers, both in the brain and peripherally 
(reviewed in [2]). What is new is the idea that inﬂ  am-
matory processing makes a direct contribution to disease 
development – that it is part of a causal pathway to 
disease. Hypertension has also been highlighted as a risk 
factor for AD in previous epidemiological studies, 
although the results have been mixed [3]. What the van 
Exel study now suggests, however, is that this risk is 
mediated through genetic susceptibility.
Th  ese ﬁ  ndings become more interesting when juxta-
posed with those emerging from recent genetic studies, 
including our own. Th   e advent of powerful genome-wide 
association studies has at last provided ﬁ  rm evidence for 
new risk genes for Alzheimer’s disease. We identiﬁ  ed two 
new susceptibility genes for AD – CLU and PICALM [4] – 
and when we put our data together with a similar study 
undertaken by a French group, a third gene was added to 
the list, CR1  [5]. Both CLU, coding for clusterin, and 
CR1, complement receptor 1, are involved in inﬂ  am-
mation/innate immunity. Clusterin is a complement 
inhibitor and can suppress complement activation 
observed in AD, and CR1 helps instigate the adaptive 
immune response [6].
Both apolipoprotein E, a known risk factor for AD, and 
clusterin regulate cholesterol and lipid metabolism of the 
brain, which is disturbed in AD. It is possible that their 
eﬀ  ects on the processing of cholesterol in the periphery 
could in turn aﬀ   ect hypertension, amongst others 
processes. Of course, these molecules have other 
functions that may contribute to disease development, so 
we must remain cautious in our interpretation. Note-
worthy, however, is that a variety of research strategies 
are producing independent evidence converging on the 
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van Exel and colleagues present an elegant 
study testing relationships between vascular and 
infl  ammatory traits and the risk of Alzheimer’s 
disease (AD) development. They compared middle-
aged off  spring of AD cases with similar off  spring 
of nondemented parents and observed greater 
infl  ammatory response to challenge and increased 
hypertension in those at high genetic risk. These 
observations join a growing body of evidence 
implicating infl  ammation/innate immunity as a 
crucial component in disease development. Recent 
discoveries of new risk genes for Alzheimer’s 
disease also implicate innate immunity and to some 
extent vascular health as potentially important in 
pathogenesis. Further identifi  cation and refi  nement 
of putative disease mechanisms is likely as the genetic 
architecture of AD is uncovered through current large-
scale association and sequencing studies.
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health in AD development.
We already know that genes play an important role in 
AD development, with studies showing heritability of 
between 56 and 79% [4]. It is therefore encouraging that 
further work characterising the genetic architecture of 
AD is well underway. Larger genome-wide association 
studies involving tens of thousands of AD cases and 
controls should report their ﬁ   ndings within the year. 
Th   ese results will no doubt identify several more 
common susceptibility genes conferring risk for AD. In 
addition, advances in sequencing technologies will allow 
large-scale inter  ro  gations of coding regions in the 
genome likely to detect rare variants of strong eﬀ  ect. 
Together these research strategies will map out much of 
the genetic architecture of AD in the near future. But 
most importantly, these genetic research strategies will 
give us the best indication yet of the mechanisms that 
contribute directly to AD development.
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